Research ArticleEverolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial

Background & AimsPolycystic liver disease (PLD) is associated with autosomal dominant polycystic kidney disease (ADPKD) or autosomal dominant polycystic liver disease (PCLD). The resulting hepatomegaly compromises quality of life. Somatostatin analogues reduce PLD volume by approximately 5% when given for 6-12 months. A pilot trial in 16 ADPKD patients demonstrated that sirolimus, an mTOR inhibitor, reduced PLD volume by 26%. The aim of this study was to assess the PLD volume reducing effect of everolimus and octreotide relative to octreotide monotherapy.MethodsWe designed a randomized controlled trial that compared 48 weeks of everolimus 2.5 mg daily, combined with octreotide 40 mg intramuscularly every 4 weeks, to octreotide monotherapy. We included PCLD and ADPKD patients. Exclusion criteria were MDRD-GFR <60 ml/min/1.73 m2 and liver volume <2500 ml. Primary outcome was change in liver volume measured with CT-volumetry.ResultsWe randomized 44 PLD patients (29 PCLD, 15 ADPKD, 89% female) to treatment with octreotide (n = 23) or octreotide-everolimus (n = 21). Liver volume decreased by 3.5% (p <0.01) in the monotherapy arm, compared to 3.8% with combination therapy (p <0.01). The difference between treatment arms was not significant (p = 0.73).ConclusionsAdding everolimus to octreotide in PLD does not increase the liver volume reducing effect of octreotide.